Biocryst Pharmaceuticals INC (BCRX) — 8-K Filings

All 8-K filings from Biocryst Pharmaceuticals INC. Browse 34 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (34)

BioCryst Pharmaceuticals Files 8-K — Dec 12, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on December 12, 2025, reporting on other events and financial statements. The filing does not contain specific finan
8-K Filing — Dec 11, 2025
BioCryst Pharmaceuticals Files 8-K — Dec 3, 2025 Risk: low
On December 3, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific mater
8-K Filing — Nov 3, 2025
BioCryst Pharmaceuticals Reports 8-K Filing — Oct 14, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. announced on October 14, 2025, several key events including the entry into a material definitive agreement, updates on its result
BioCryst Pharmaceuticals Files 8-K — Oct 1, 2025 Risk: medium
On October 1, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and report
BioCryst Pharmaceuticals Reports Leadership Changes — Aug 11, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. filed an 8-K on August 11, 2025, reporting on the departure of directors or certain officers, the election of directors, and comp
BioCryst Pharmaceuticals Files 8-K on Financials — Aug 4, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on August 4, 2025, reporting on its results of operations and financial condition. The filing also includes informat
BioCryst Pharmaceuticals Announces Board and Executive Changes — Jul 31, 2025 Risk: medium
On July 25, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes
BioCryst Pharmaceuticals Adds Directors, Updates Officer Compensation — Jul 7, 2025 Risk: low
On July 7, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the election of two new directors, Dr. A
BioCryst Pharmaceuticals Enters Material Definitive Agreement — Jun 30, 2025 Risk: medium
On June 27, 2025, BioCryst Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executiv
BioCryst Pharmaceuticals Files 8-K — Jun 27, 2025 Risk: low
On June 27, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indi
BioCryst Pharmaceuticals Files 8-K: Other Events — Jun 25, 2025 Risk: medium
On June 23, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details
BioCryst Pharmaceuticals Reports Director/Officer Changes & More — Jun 16, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting events as of June 11, 2025. The filing covers the departure of directors or certain offi
BioCryst Pharmaceuticals Announces Executive and Director Changes — Jun 4, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. announced on May 31, 2025, changes in its executive and director roles. The filing details the departure of certain officers and
BioCryst Pharmaceuticals Files 8-K — May 14, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on May 14, 2025, reporting other events and financial statements. The filing does not contain specific financial fig
BioCryst Pharmaceuticals Files 8-K — May 5, 2025 Risk: low
On May 5, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial st
BioCryst Pharmaceuticals Files 8-K on Leadership and Compensation — May 1, 2025 Risk: medium
On April 30, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The f
BioCryst Pharmaceuticals Announces Board and Executive Changes — Apr 10, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. announced on April 6, 2025, changes in its executive team. The company elected two new directors, Dr. Robert J. Radcliff and Ms.
BioCryst Pharmaceuticals Files 8-K — Mar 11, 2025 Risk: medium
On March 10, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a significant development not cov
BioCryst Pharmaceuticals Announces Board and Compensation Changes — Mar 4, 2025 Risk: medium
BioCryst Pharmaceuticals, Inc. announced on February 28, 2025, changes in its board of directors and executive compensation arrangements. The filing details the
BioCryst Pharmaceuticals Files 8-K on Financials — Feb 24, 2025 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on February 24, 2025, reporting on its results of operations and financial condition. The filing also included discl
BioCryst Pharmaceuticals Files 8-K Report — Jan 13, 2025 Risk: low
On January 13, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of events and does not disclose specific
BioCryst Pharmaceuticals Files 8-K on Financials — Jan 10, 2025 Risk: low
On January 10, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditi
BioCryst Pharmaceuticals Files 8-K — Jan 8, 2025 Risk: medium
On January 8, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material informatio
BioCryst Pharmaceuticals Files 8-K — Nov 4, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on November 4, 2024, reporting on its results of operations and financial condition. The filing also includes Regula
BioCryst Pharmaceuticals Files 8-K — Oct 2, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on October 2, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does n
BioCryst Pharmaceuticals Files 8-K — Sep 30, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on September 30, 2024, reporting on various events. The filing includes financial statements and exhibits, indicatin
BioCryst Pharmaceuticals Files 8-K on Financials — Aug 5, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on August 5, 2024, reporting on its results of operations and financial condition. The filing also includes Regulati
BioCryst Appoints New Chief Medical Officer — Jun 13, 2024 Risk: medium
BioCryst Pharmaceuticals, Inc. announced on June 12, 2024, the appointment of Dr. William P. Sheridan as Chief Medical Officer. Dr. Sheridan previously served a
BioCryst Pharmaceuticals Files 8-K on Financials — May 6, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation
BioCryst Pharmaceuticals Files 8-K on Financial Results — Feb 26, 2024 Risk: low
BioCryst Pharmaceuticals, Inc. filed an 8-K on February 26, 2024, to report its financial condition and results of operations. The filing also included a Regula
BioCryst Amends Bylaws, Easing Director Removal Process — Jan 18, 2024
BioCryst Pharmaceuticals, Inc. filed an 8-K on January 18, 2024, to report an amendment to its bylaws, effective January 16, 2024. The amendment changed the req
BioCryst 8-K Signals New Financial Disclosures on Jan 5 — Jan 8, 2024
BioCryst Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 5, 2024, related to 'Results of Operations and Finan

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX